SLP Simulations Plus Inc: רווח למניה בשנים עשר החודשים האחרונים

Simulations Plus, Inc. (SLP) operates within its own business cycle, independent of global economic fluctuations, which transforms it into a reliable defensive asset. The asset's market valuation trend on the GURU.Markets platform, where the indicator stands at 112.80, confirms the success of the strategy to implement digital simulations as a replacement for real-world pharmacological testing. Simulations Plus, Inc. (SLP) generates revenue through the sale of specialized software and high-margin B2B subscriptions for drug modeling systems.

This metric measures the dynamics of net income per share over the last twelve months relative to the same period last year. Analyzing the EPS YoY growth rate (trailing 12 months) allows an investor to assess the sustainability of fundamental momentum and identify signs of slowing growth. The current value of 112.80 reflects the efficiency of the business capitalization. Stable demand for medical research makes Simulations Plus, Inc. (SLP) a defensive asset, independent of global macroeconomic fluctuations.